紫杉醇和顺铂在老年食道癌患者中的疗效探究  

Study on the Efficacy of Paclitaxel and Cisplatin in Elderly Patients with Esophageal Cancer

作　　者：孔祥训 KONG Xiang-xun(Department of Oncology and Hematology,People's Hospital of Dingtao District,Heze,Shandong Province,274100 China)

机构地区：[1]菏泽市定陶区人民医院肿瘤血液科,山东菏泽274100

出　　处：《中外医疗》2020年第20期83-85,共3页China & Foreign Medical Treatment

摘　　要：目的研究紫杉醇和顺铂治疗对于老年食道癌的治疗效果,从而为老年食道癌的治疗提供一定的临床帮助。方法简单随机选取该院接收的100例老年食道癌患者,该次实验研究的时间范围为2017年7月—2019年7月,采用随机抽签分组法将这些患者分为氟尿嘧啶治疗组与紫杉醇治疗组,其中氟尿嘧啶治疗组患者50例,紫杉醇治疗组患者50例,氟尿嘧啶治疗组患者采用氟尿嘧啶联合顺铂进行治疗,紫杉醇治疗组患者采用紫杉醇和顺铂联合治疗,将两组患者的治疗有效率、不良反应发生情况、肿瘤进展时间、平均生存时间进行比较。结果①氟尿嘧啶治疗组患者的治疗效果劣于紫杉醇治疗组患者,两组的治疗有效例数分别为25例、35例,两组之间的治疗效果差异有统计学意义(χ2=4.167,P=0.041)。②氟尿嘧啶治疗组患者的治疗满意度劣于紫杉醇治疗组患者,两组的满意例数分别为47例、40例,两组之间的数据差异有统计学意义(χ2=4.332,P=0.037)。③氟尿嘧啶治疗组患者的肿瘤进展时间、平均生存时间低于紫杉醇治疗组患者,分别为(5.02±1.14)个月和(6.88±1.22)个月,(9.88±2.66)个月和(11.25±2.09)个月。两组之间的数据差异有统计学意义(t=7.877、3.031,P=0.000、0.003)。④氟尿嘧啶治疗组患者的不良反应发生概率高于紫杉醇治疗组患者,不良反应人数分别为7例、1例;两组之间的数据差异有统计学意义(χ2=4.891,P=0.027)。结论老年食道癌患者进行紫杉醇联合顺铂联合治疗的治疗效果良好,可以有效的推迟肿瘤进展时间,延长患者的生存周期,该药物的安全性较高,患者的不良反应发生概率较低。Objective To study the therapeutic effect of paclitaxel and cisplatin on elderly esophageal cancer,so as to provide some clinical help for the treatment of elderly esophageal cancer.Methods 100 elderly esophageal cancer patients received in the hospital were easy randomly selected.The time range of this experimental study was from July 2017 to July 2019.These patients were divided into fluorouracil treatment group by random lot grouping.Paclitaxel treatment group,including 50 patients in the fluorouracil treatment group,50 patients in the paclitaxel treatment group,patients in the fluorouracil treatment group were treated with fluorouracil and cisplatin,and patients in the paclitaxel treatment group were treated with paclitaxel and cisplatin.Comparison of efficiency,occurrence of adverse reactions,tumor progression time,and mean survival time.Results 1.The therapeutic effect of the patients in the fluorouracil treatment group was inferior to the patients in the paclitaxel treatment group.The number of effective treatment cases in the two groups was 25 cases and 35 cases,respectively.The difference in treatment effect between the two groups was statistically significant(χ2=4.167,P=0.041).2.The treatment satisfaction of patients in the fluorouracil treatment group was worse than that in the paclitaxel treatment group.The number of satisfactory cases in the two groups was 47 cases and 40 cases,respectively.The data difference between the two groups was statistically significant(χ2=4.332,P=0.037).3.The tumor progression time and average survival time of patients in the fluorouracil group were lower than those in the paclitaxel group,which were(5.02±1.14)months and(6.88±1.22)months,(9.88±2.66)months and(11.25±2.09)months.The data difference between the two groups was statistically significant(t=7.877,3.031,P=0.000,0.003).4.The incidence of adverse reactions in the fluorouracil-treated group was higher than that in the paclitaxel-treated group,and the number of adverse reactions was 7 cases and 1 case,respectivel

关 键 词：紫杉醇 顺铂 治疗 效果 老年食道癌 安全性 疗效 

分 类 号：R735[医药卫生—肿瘤]